Masteron Enanthate 200

VGL Fitness Masteron Enanthate 200 by Vanguard Labs delivers 200 mg/ml of high-quality drostanolone enanthate, a longer-acting DHT-derived compound commonly used during cutting and recomposition phases. Designed to promote a harder, drier physique with enhanced muscle density, this long-ester formulation provides more stable blood levels with less frequent injections compared to short esters.

Unlike aromatising compounds, Masteron Enanthate from Vanguard Labs does not convert to oestrogen, making VGL Fitness Mast Enth 200 a popular addition to testosterone-based cycles where users seek improved cosmetic refinement, strength retention, and reduced subcutaneous water. Due to its strong androgenic profile and lipid impact, this compound is best suited to experienced users who understand cardiovascular monitoring, E2 management, and DHT-related risk considerations.

Masteron Enanthate – Harm Reduction Crib Sheet

Compound: Drostanolone Enanthate (Masteron Enanthate)
Class: Dihydrotestosterone (DHT)-Derived Anabolic-Androgenic Steroid (AAS)
Administration: Intramuscular injection (IM)

Dosage

• Performance Use: 400–600 mg/week
• Cutting/Hardening Use: 300–500 mg/week
• Injection frequency: 2x/week (e.g. Monday/Thursday)

Half-Life

• ~7 to 10 days
• Stable levels maintained with injections every 3.5 days

Benefits

• Lean, dry muscle gains
• Hardening and drying effect (aesthetic improvement)
• No aromatisation → No water retention or gynecomastia
• May reduce oestrogenic activity when stacked with aromatising compounds
• Mildly anti-oestrogenic and anti-prolactin properties

Side Effects

• Androgenic: Acne, oily skin, hair thinning (especially in those genetically predisposed)
• Suppression: Reduces natural testosterone production
• Lipid profile: ↓ HDL, ↑ LDL (milder than most orals or 19-nors)
• Mild enlargement of prostate (in susceptible individuals)
• Sexual function: May reduce libido in the absence of a test base

Risks

• Cardiovascular: Adverse effects on HDL/LDL cholesterol
• Endocrine: Testosterone suppression
• Reproductive: Infertility during cycle
• Psychological: Rare, but mild irritability or mood shifts possible
• Hepatotoxicity: None (injectable)

Risk Mitigation

• Bloodwork: Full panel pre-, mid-, and post-cycle (lipids, CBC, TT/FT, E2)
• Testosterone base: Strongly recommended to avoid sexual side effects
• Lipid support: Omega-3s, high-fibre diet, cardio
• Hair loss support: Not responsive to finasteride (DHT-derived)
• Injection protocol: Sterile technique, site rotation

Post-Cycle Therapy (PCT)

If not transitioning to TRT

• Start: 10–14 days after last injection
• Tamoxifen (Nolvadex):
  • 40 mg/day (Weeks 1–2)
  • 20 mg/day (Weeks 3–4)
• Optional – Clomiphene (Clomid): 50 mg/day for 4 weeks
• Follow-up labs: 4–6 weeks post-PCT